Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
hematopoietic stem-cell transplantation
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "hematopoietic stem-cell transplantation" in MCE Product Catalog:
2
Target:
Research Areas:
Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. Burixafor hydrobromide inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. Burixafor hydrobromide mobilizes CD34 + hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood. Burixafor hydrobromide can be used for research on autologous hematopoietic stem cell transplantation (ASCT) .
1
1 Cited Publications
Cat. No.: HY-P99376
CAS No.: 2108782-45-0
Synonyms: OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)
1
Cosalane (NSC 658586) is a CCR7 (IC50 = 2.43 μM) and CXCR2 antagonist (IC50 = 0.66 μM). Cosalane is an inhibitor of HIV replication with a wide range of activity against HIV-1 isolates, HIV-2, Rauscher murine leukemia virus, HSV-1, HSV-2 and human cytomegalovirus. Cosalane inhibits both attachment of gp120 to CD4. Cosalane inhibits human and murine CCR7 in response to both CCL19 and CCL21 agonists. Cosalane can be studied in research for HIV or attenuating acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) .
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .
Cat. No.: HY-P991294
Target:
Research Areas:
Cat. No.: HY-19867
CAS No.: 1191448-17-5
Synonyms: TG-0054
Burixafor (TG-0054) is a potent CXCR4 antagonist with a pIC50 of 7.4. Burixafor inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. Burixafor mobilizes CD34 + hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood. Burixafor can be used for research on autologous hematopoietic stem cell transplantation (ASCT) .
Cat. No.: HY-102088
CAS No.: 77408-67-4
P18IN011 is an inhibitor that specifically targets the interaction between p18(INK4C) and CDK6, with an IC50 of 3.61 μM against mouse p18INK4C. P18IN011 relieves p18-mediated CDK6 inhibition, thereby effectively regulating the G1 phase cell cycle checkpoint. P18IN011 significantly enhances the proliferation, self-renewal and bone marrow reconstitution abilities of hematopoietic stem cells, and increases the frequency of primitive hematopoietic cells to promote cobblestone area formation. Acting specifically on p18-expressing hematopoietic cells via CDK4/6, P18IN011 not only supports the ex vivo expansion of human umbilical cord blood hematopoietic stem cells, but also maintains their long-term reconstitution capacity during in vitro culture to enable multi-lineage transplantation .
Cat. No.: HY-L171
4,388 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.
MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
